Search

BiomX and Adaptive Phage Therapeutics have announced they will merge! They concurrently announce new financing of $50 million, which will help advance the combined company’s two Phase 2 assets: one for CF and one for diabetic foot ulcers.

Armata Pharmaceuticals has announced a $35 million credit agreement with its largest shareholder, Innoviva.

Adaptive Phage Therapeutics has received $12 million from Deerfield Management and the AMR Action Fund as part of a new $24 million investment.

Fixed Phage, a Glasgow based biotech company, has secured £1.5m investment to further scale development and commercialisation of its phage technology in the fight against antimicrobial resistance.